Date: 2014-09-17
Type of information: Nomination
Compound: international headquarters in Dublin
Company: PTC Therapeutics (USA - NJ)
Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases
Type agreement: nomination - opening of new premises
Action mechanism:
Disease: Duchenne muscular dystrophy
Details:
Financial terms:
Latest news:
- • On September 17, 2014, PTC Therapeutics announced the expansion of its global presence with the addition of key executives to leadership positions in PTC's global commercial team and the establishment of its international headquarters in Dublin, Ireland. Significant pre-launch activities are well underway as PTC prepares for the commercial launch of Translarna™ (ataluren) in the European Union. In August of this year, Translarna™ received approval from the European Medicines Agency for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
PTC has recently expanded its leadership team within the commercial organization with the appointment of Adrian Haigh as Senior Vice President & General Manager of the EMEA Region. Adrian joins PTC from Gentium SpA, where he held the position of Senior Vice President, Commercial Operations. While at Gentium, Adrian was responsible for building and managing the company\'s commercial and medical affairs organization. Prior to joining Gentium, Adrian served as Regional Vice President, Commercial Operations at Biogen Idec, where he managed several affiliates and also the global distribution business. The company has also appointed senior executives with rare disease and commercial launch experience for key countries including Germany, the UK, France, Italy and the Nordic Region. PTC\'s international headquarters in Dublin will serve as the central hub for the commercial launch of Translarna to take advantage of its location with respect to PTC\'s third party manufacturing and supply chain. In addition, PTC has begun establishing subsidiaries in each of the key European countries where Translarna is expected to initially become commercially available.
Is general: Yes
